A detailed history of National Bank Of Canada transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, National Bank Of Canada holds 102,437 shares of VRTX stock, worth $51.5 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares
102,437
Previous 136,133 24.75%
Holding current value
$51.5 Million
Previous $56.9 Million 15.62%
% of portfolio
0.08%
Previous 0.1%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 02, 2024

SELL
$392.81 - $485.53 $13.2 Million - $16.4 Million
-33,696 Reduced 24.75%
102,437 $48 Million
Q1 2024

May 13, 2024

SELL
$407.69 - $446.08 $40.9 Million - $44.7 Million
-100,264 Reduced 42.41%
136,133 $56.9 Million
Q4 2023

Feb 06, 2024

BUY
$343.0 - $410.68 $38.4 Million - $46 Million
112,007 Added 90.05%
236,397 $96.2 Million
Q3 2023

Oct 10, 2023

SELL
$338.18 - $362.46 $25 Million - $26.8 Million
-74,020 Reduced 37.31%
124,390 $43.3 Million
Q2 2023

Jul 26, 2023

BUY
$314.42 - $351.91 $46.4 Million - $52 Million
147,671 Added 291.04%
198,410 $69.8 Million
Q1 2023

Apr 12, 2023

SELL
$283.23 - $323.1 $24.8 Million - $28.2 Million
-87,430 Reduced 63.28%
50,739 $16 Million
Q4 2022

Jan 24, 2023

BUY
$285.76 - $321.48 $25.6 Million - $28.7 Million
89,411 Added 183.38%
138,169 $0
Q3 2022

Oct 13, 2022

BUY
$273.83 - $305.53 $2.09 Million - $2.33 Million
7,622 Added 18.53%
48,758 $14.3 Million
Q2 2022

Jul 28, 2022

BUY
$234.96 - $292.55 $1.19 Million - $1.48 Million
5,060 Added 14.03%
41,136 $11.7 Million
Q1 2022

May 05, 2022

BUY
$221.42 - $260.97 $6.5 Million - $7.66 Million
29,337 Added 435.33%
36,076 $10.3 Million
Q4 2021

Jan 24, 2022

BUY
$177.01 - $223.45 $1.19 Million - $1.51 Million
6,739 New
6,739 $1.49 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track National Bank Of Canada Portfolio

Follow National Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of National Bank Of Canada , based on Form 13F filings with the SEC.

News

Stay updated on National Bank Of Canada with notifications on news.